S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
Log in
OTCMKTS:CYTR

CytRx Competitors

$3.59
+0.12 (+3.46 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.10
Now: $3.59
$3.60
50-Day Range
$2.01
MA: $2.80
$4.15
52-Week Range
$0.35
Now: $3.59
$5.00
Volume78,204 shs
Average Volume178,105 shs
Market Capitalization$130.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12

Competitors

CytRx (OTCMKTS:CYTR) Vs. GRTS, FUSN, HARP, AVRO, CBMG, and FRLN

Should you be buying CYTR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to CytRx, including Gritstone Oncology (GRTS), Fusion Pharmaceuticals (FUSN), Harpoon Therapeutics (HARP), AVROBIO (AVRO), Cellular Biomedicine Group (CBMG), and Freeline Therapeutics (FRLN).

CytRx (OTCMKTS:CYTR) and Gritstone Oncology (NASDAQ:GRTS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares CytRx and Gritstone Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytRx$250,000.00523.85$-7,160,000.00N/AN/A
Gritstone Oncology$4.36 million120.13$-94,430,000.00($2.81)-4.94

CytRx has higher earnings, but lower revenue than Gritstone Oncology.

Institutional and Insider Ownership

0.0% of CytRx shares are held by institutional investors. Comparatively, 59.0% of Gritstone Oncology shares are held by institutional investors. 22.0% of CytRx shares are held by insiders. Comparatively, 38.0% of Gritstone Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

CytRx has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for CytRx and Gritstone Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CytRx0000N/A
Gritstone Oncology10202.33

Gritstone Oncology has a consensus price target of $22.3333, indicating a potential upside of 61.02%. Given Gritstone Oncology's higher probable upside, analysts plainly believe Gritstone Oncology is more favorable than CytRx.

Profitability

This table compares CytRx and Gritstone Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CytRxN/A-62.90%-50.65%
Gritstone Oncology-2,962.52%-101.31%-68.78%

Summary

CytRx beats Gritstone Oncology on 6 of the 11 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Fusion Pharmaceuticals and CytRx's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
CytRx$250,000.00523.85$-7,160,000.00N/AN/A

CytRx has higher revenue and earnings than Fusion Pharmaceuticals.

Insider and Institutional Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of CytRx shares are owned by institutional investors. 22.0% of CytRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Fusion Pharmaceuticals and CytRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
CytRxN/A-62.90%-50.65%

Analyst Ratings

This is a breakdown of current recommendations for Fusion Pharmaceuticals and CytRx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
CytRx0000N/A

Fusion Pharmaceuticals currently has a consensus target price of $24.3333, indicating a potential upside of 120.61%. Given Fusion Pharmaceuticals' higher probable upside, research analysts clearly believe Fusion Pharmaceuticals is more favorable than CytRx.

Summary

Fusion Pharmaceuticals beats CytRx on 5 of the 8 factors compared between the two stocks.

CytRx (OTCMKTS:CYTR) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares CytRx and Harpoon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytRx$250,000.00523.85$-7,160,000.00N/AN/A
Harpoon Therapeutics$5.78 million79.61$-55,570,000.00($2.55)-7.11

CytRx has higher earnings, but lower revenue than Harpoon Therapeutics.

Risk and Volatility

CytRx has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of CytRx shares are held by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are held by institutional investors. 22.0% of CytRx shares are held by insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares CytRx and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CytRxN/A-62.90%-50.65%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Analyst Recommendations

This is a summary of current ratings and recommmendations for CytRx and Harpoon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CytRx0000N/A
Harpoon Therapeutics00703.00

Harpoon Therapeutics has a consensus target price of $31.5714, indicating a potential upside of 74.14%. Given Harpoon Therapeutics' higher possible upside, analysts clearly believe Harpoon Therapeutics is more favorable than CytRx.

Summary

Harpoon Therapeutics beats CytRx on 6 of the 11 factors compared between the two stocks.

AVROBIO (NASDAQ:AVRO) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Insider and Institutional Ownership

86.7% of AVROBIO shares are held by institutional investors. Comparatively, 0.0% of CytRx shares are held by institutional investors. 4.8% of AVROBIO shares are held by company insiders. Comparatively, 22.0% of CytRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares AVROBIO and CytRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVROBION/A-51.33%-47.65%
CytRxN/A-62.90%-50.65%

Risk and Volatility

AVROBIO has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, CytRx has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500.

Valuation & Earnings

This table compares AVROBIO and CytRx's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVROBION/AN/A$-72,960,000.00($2.66)-4.31
CytRx$250,000.00523.85$-7,160,000.00N/AN/A

CytRx has higher revenue and earnings than AVROBIO.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AVROBIO and CytRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVROBIO03502.63
CytRx0000N/A

AVROBIO currently has a consensus price target of $27.8333, suggesting a potential upside of 142.87%. Given AVROBIO's higher possible upside, research analysts plainly believe AVROBIO is more favorable than CytRx.

Summary

AVROBIO beats CytRx on 5 of the 9 factors compared between the two stocks.

Cellular Biomedicine Group (NASDAQ:CBMG) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

22.0% of Cellular Biomedicine Group shares are owned by institutional investors. Comparatively, 0.0% of CytRx shares are owned by institutional investors. 8.5% of Cellular Biomedicine Group shares are owned by company insiders. Comparatively, 22.0% of CytRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Cellular Biomedicine Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, CytRx has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Cellular Biomedicine Group and CytRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellular Biomedicine Group01002.00
CytRx0000N/A

Cellular Biomedicine Group currently has a consensus price target of $19.00, suggesting a potential downside of 3.80%. Given Cellular Biomedicine Group's higher probable upside, equities analysts plainly believe Cellular Biomedicine Group is more favorable than CytRx.

Earnings and Valuation

This table compares Cellular Biomedicine Group and CytRx's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellular Biomedicine Group$340,000.001,131.44$-49,980,000.00N/AN/A
CytRx$250,000.00523.85$-7,160,000.00N/AN/A

CytRx has lower revenue, but higher earnings than Cellular Biomedicine Group.

Profitability

This table compares Cellular Biomedicine Group and CytRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellular Biomedicine GroupN/A-144.80%-61.68%
CytRxN/A-62.90%-50.65%

Summary

CytRx beats Cellular Biomedicine Group on 5 of the 9 factors compared between the two stocks.

CytRx (OTCMKTS:CYTR) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Valuation and Earnings

This table compares CytRx and Freeline Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytRx$250,000.00523.85$-7,160,000.00N/AN/A
Freeline TherapeuticsN/AN/AN/AN/AN/A

Freeline Therapeutics has lower revenue, but higher earnings than CytRx.

Insider & Institutional Ownership

0.0% of CytRx shares are held by institutional investors. Comparatively, 38.5% of Freeline Therapeutics shares are held by institutional investors. 22.0% of CytRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for CytRx and Freeline Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CytRx0000N/A
Freeline Therapeutics01502.83

Freeline Therapeutics has a consensus price target of $26.00, indicating a potential upside of 79.43%. Given Freeline Therapeutics' higher possible upside, analysts clearly believe Freeline Therapeutics is more favorable than CytRx.

Profitability

This table compares CytRx and Freeline Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CytRxN/A-62.90%-50.65%
Freeline TherapeuticsN/AN/AN/A

Summary

Freeline Therapeutics beats CytRx on 5 of the 7 factors compared between the two stocks.


CytRx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.87+2.2%$523.79 million$4.36 million-4.85Upcoming Earnings
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.03+2.0%$460.24 millionN/A0.00
HARP
Harpoon Therapeutics
1.5$18.13+2.6%$460.14 million$5.78 million-8.51Upcoming Earnings
AVROBIO logo
AVRO
AVROBIO
1.7$11.46+1.2%$417.73 millionN/A-3.47Upcoming Earnings
Analyst Report
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75+0.0%$384.69 million$340,000.00-6.98
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$14.49+5.6%$375.60 millionN/A0.00Analyst Report
Gap Up
Opthea logo
OPT
Opthea
1.5$8.55+6.5%$360.88 millionN/A0.00High Trading Volume
Innate Pharma logo
IPHYF
Innate Pharma
0.6$4.53+0.0%$355.79 million$96.12 million0.00
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.41+2.3%$348.31 million$96.12 million-12.97Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.54+2.6%$341.10 millionN/A0.00Upcoming Earnings
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.15+6.2%$339.03 million$250,000.00-3.27
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.57+0.1%$336.94 millionN/A0.00Upcoming Earnings
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.16+0.5%$321.86 million$2.91 million-2.15Earnings Announcement
Analyst Revision
Gap Down
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81+0.6%$313.91 million$8.15 million-1.45Gap Down
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.50+7.1%$310.94 millionN/A-5.47
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$14.30+4.1%$308.18 millionN/A0.00Upcoming Earnings
Gap Down
Surface Oncology logo
SURF
Surface Oncology
1.3$7.36+1.9%$299.38 million$15.36 million-11.15
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.06+0.2%$294.74 millionN/A-3.73Upcoming Earnings
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47+0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.26+0.9%$279.49 million$4.13 million-5.01Upcoming Earnings
News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$11.26+4.1%$270.86 millionN/A-8.22
Lineage Cell Therapeutics logo
LCTX
Lineage Cell Therapeutics
1.6$1.77+4.5%$265.48 million$3.52 million-9.83Upcoming Earnings
News Coverage
Gap Up
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.86+2.8%$249.84 millionN/A-4.91Upcoming Earnings
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$5.09+18.3%$215.09 million$1.45 million-1.79High Trading Volume
Increase in Short Interest
Analyst Revision
Gap Down
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.50+0.5%$207.10 million$104.39 million-3.35
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.66+4.7%$198.79 million$2.45 million-2.19Analyst Report
Axcella Health logo
AXLA
Axcella Health
1.6$5.28+1.5%$198.22 millionN/A-2.46
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.15+1.8%$197.39 millionN/A-5.70Gap Down
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.04+2.5%$192.88 million$29.35 million-2.37Upcoming Earnings
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.28+0.7%$189.30 millionN/A-8.88Upcoming Earnings
Genfit logo
GNFT
Genfit
1.3$4.87+0.6%$189.24 million$45.88 million-2.47Gap Down
INmune Bio logo
INMB
INmune Bio
1.5$13.12+9.1%$176.44 millionN/A-13.53Earnings Announcement
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.5$13.20+1.6%$168.68 million$2.33 million0.00
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$8.04+1.1%$161.19 millionN/A-2.05Gap Up
Protalix BioTherapeutics logo
PLX
Protalix BioTherapeutics
1.3$4.32+3.0%$158.26 million$54.69 million-3.51Upcoming Earnings
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.05+1.6%$157.53 millionN/A0.00Upcoming Earnings
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.51+0.1%$154.89 millionN/A-2.97Earnings Announcement
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.87+2.5%$153.55 million$20,000.000.00
PHGE
BiomX
0.6N/AN/A$152.50 millionN/A0.00
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$14.53+0.8%$148.58 millionN/A0.00High Trading Volume
Champions Oncology logo
CSBR
Champions Oncology
1.1$11.02+6.4%$147.33 million$32.12 million-84.77Upcoming Earnings
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.64+1.9%$141.29 millionN/A-1.82
Dyadic International logo
DYAI
Dyadic International
1.3$5.13+3.5%$140.98 million$1.68 million-15.09
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.56+2.6%$124.86 million$23.05 million-2.03Earnings Announcement
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.9$8.03+2.4%$124.30 million$3 million-2.58
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.46+1.4%$123.60 millionN/A-3.30
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.40+3.8%$115.30 million$20.92 million-1.38
Armata Pharmaceuticals logo
ARMP
Armata Pharmaceuticals
1.7$4.73+5.1%$97.48 millionN/A-3.07
AIM
AIM ImmunoTech
1.7$2.01+2.0%$81.78 million$140,000.000.00Upcoming Earnings
News Coverage
Gap Down
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$10.84+7.1%$79.49 millionN/A0.00
This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.